| Literature DB >> 32600823 |
R Kassir1, L Rebibo2, L Genser3, A Sterkers4, M-C Blanchet5, F Pattou6, S Msika7.
Abstract
Bariatric/metabolic surgery was paused during the Covid-19 pandemic. The impact of social confinement and the interruption of this surgery on the population with obesity has been underestimated, with weight gain and worsened comorbidities. Some candidates for this surgery are exposed to a high risk of mortality linked to the pandemic. Obesity and diabetes are two major risk factors for severe forms of Covid-19. The only currently effective treatment for obesity is metabolic surgery, which confers prompt, lasting benefits. It is thus necessary to resume such surgery. To ensure that this resumption is both gradual and well-founded, we have devised a priority ranking plan. The flow charts we propose will help centres to identify priority patients according to a benefit/risk assessment. Diabetes holds a central place in the decision tree. Resumption patterns will vary from one centre to another according to human, physical and medical resources, and will need adjustment as the epidemic unfolds. Specific informed consent will be required. Screening of patients with obesity should be considered, based on available knowledge. If Covid-19 is suspected, surgery must be postponed. Emphasis must be placed on infection control measures to protect patients and healthcare professionals. Confinement is strongly advocated for patients for the first month post-operatively. Patient follow-up should preferably be by teleconsultation.Entities:
Keywords: Bariatric surgery; Covid-19; Guidelines; Obesity; Pandemic
Mesh:
Year: 2020 PMID: 32600823 PMCID: PMC7274637 DOI: 10.1016/j.jviscsurg.2020.06.005
Source DB: PubMed Journal: J Visc Surg ISSN: 1878-7886 Impact factor: 2.043
Strategies for resuming bariatric surgery.
| What patients? | Justification | Advantages | Risks | Needs for IC beds | |
|---|---|---|---|---|---|
| Strategy 1 | Operate on patients whose need is high | Deterioration in health very probable within 6 months | Very high benefit if post-operative effects are simple | Some of these patients have the highest risk of complications | High |
| Strategy 2 | Operate on patients with the least possible comorbidities | Reduces the number of patients with obesity on waiting lists for weight-loss surgery, so reducing the number of vulnerable patients | Benefits high but less than in Strategy 1 | Patients are less at risk | Rare |
| Strategy 3 | Operate on patients whose need is high provided the risk of morbidity is very low | 1/This metabolic surgery is the only effective treatement for obesity | 1/Very favourable benefit/risk ratio at both individual and public health scales | Low | Rare |
Figure 1Benefits of weight-loss surgery by category during the Covid-19 crisis.
Figure 2Risks of morbidity in weight-loss surgery by category during the Covid-19 crisis.
Figure 3Categories of patients undergoing primary weight-loss surgery in the current Covid-19 setting. BRR: benefit/risk ratio.
Figure 4Resumption of overall activity according to the evolution of the Covid-19 pandemic.
Figure 5Preoperative measures before scheduled surgery.